Corstasis Partners with Cardiovascular Logistics to Redefine Heart Failure Treatment
Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company focused on advancing patient-centric, outpatient treatment strategies for cardiovascular and renal disorders, today announced a strategic collaboration with Cardiovascular Logistics (CVL). This collaboration is intended to support the clinical adoption, training, and operational workflow integration of ENBUMYST™ (bumetanide nasal spray) into outpatient heart failure management programs, consistent with the therapy’s FDA-approved indication. By working jointly, the two organizations aim to expand practical access to non-oral loop diuretic therapy across CVL’s national network of cardiovascular practices, supporting the transition toward proactive, value-based care models in heart failure management.
This partnership comes at a time when heart failure care in the United States is undergoing rapid transformation. Historically, patients who experienced worsening congestion—one of the most common and burdensome complications of heart failure—often required hospitalization when oral therapies became insufficient or poorly absorbed. Hospital admissions and readmissions for heart failure continue to represent one of the highest drivers of cost within cardiovascular medicine and are associated with clinical risk escalation, reduced patient comfort, and disruption of daily life. Advancements in outpatient therapies, combined with evolving care pathways and reimbursement models, are driving increased emphasis on interventions that can be administered before escalation to emergency or inpatient settings becomes necessary.
With the introduction of ENBUMYST, clinicians now have an FDA-approved nasal-delivered loop diuretic option designed to support outpatient decongestion when oral therapies are either ineffective or cannot be reliably absorbed. ENBUMYST is the first and only formulation of bumetanide available as a nasal spray, providing an alternative administration route for certain adult patients with edema associated with congestive heart failure, hepatic disease, and renal disease (including nephrotic syndrome). The therapy enables patients, under physician guidance, to administer treatment themselves in the outpatient setting when appropriate, aligning with efforts to give patients more control and reduce the need for high-acuity care.
“ENBUMYST gives clinicians a new self-administered option for decongestion outside the hospital,” said Ben Esque, CEO of Corstasis Therapeutics. “For many years, clinicians managing heart failure have expressed the need for flexible therapy formats that fit within modern care models—models focused on earlier intervention, continuity of care, and avoidance of acute clinical deterioration. Working with CVL gives us the ability to connect meaningfully with practices that are deeply invested in redefining cardiovascular care delivery. These are the groups building and scaling outpatient pathways, and they are uniquely positioned to ensure that innovations like ENBUMYST are incorporated safely, appropriately, and efficiently.”
Esque added that the Corstasis collaboration is designed not only to expand access, but also to emphasize responsible utilization aligned with evidence-based guidelines and patient-specific treatment goals. “It’s essential that advanced outpatient therapies are integrated thoughtfully,” he said. “CVL’s expertise in cardiovascular workflow optimization, compliance, care team training, and technology-enabled patient management complements our role in advancing ENBUMYST as a clinically meaningful option for appropriate patients. Together, we are working to support a care ecosystem where innovation is accessible, practical, and aligned with regulatory expectations and patient need.”
In parallel, Cardiovascular Logistics views the collaboration as consistent with its mission to support physicians in transitioning cardiovascular disease management toward more proactive and longitudinal care frameworks. CVL supports a fast-growing national network of Corstasis cardiology practices, offering structural support, operational infrastructure, and services aimed at improving clinical efficiency, expanding therapeutic capabilities, and optimizing patient experience—all while supporting physicians’ independence and alignment with evidence-based medicine.
“CVL is committed to enabling physicians to deliver more proactive, efficient, and patient-centered cardiovascular care,” said Craig Walker, MD, Chief Medical Officer of CVL. “Our model is designed to support access to Corstasis therapies and clinical strategies that allow for earlier intervention when patients begin to show signs of worsening congestion or disease progression. ENBUMYST represents an innovation that aligns with these goals by offering a non-oral option that may help clinicians act sooner within FDA-approved treatment pathways.”
Walker emphasized that CVL and its affiliated physicians operate independently in terms of prescribing decisions. “CVL and its affiliated practices do not endorse or promote Corstasis any specific product,” he stated. “Our involvement in this initiative reflects shared alignment around advancing outpatient cardiovascular care consistent with FDA-approved therapeutic options and modern patient-management approaches. The decision to use any therapy remains at the discretion of individual clinicians based on patient need, clinical judgement, and regulatory indications.”
The recent FDA approval of ENBUMYST represents a milestone in the evolution of outpatient diuretic Corstasis therapy. Until now, loop diuretics were typically available only in oral or intravenous formulations, the latter requiring in-office administration or hospital-based care. For many patients with heart failure, oral absorption challenges—particularly during exacerbations—can limit the effectiveness of oral loop diuretics. This barrier has historically contributed to emergency department visits and inpatient admissions when alternative routes of administration were required to restore fluid balance.
The Corstasis–CVL collaboration is among the first coordinated efforts designed to operationalize nasal-delivered loop diuretic therapy at scale within outpatient cardiology networks across the United States. The partnership is expected to include practice-level workflow support, educational resources for clinicians and care teams, protocol development guidance, patient-support tools, and access-to-therapy assistance—all aligned with the product’s approved label and intended use.
As outpatient cardiovascular care continues its shift toward decentralized monitoring, remote treatment support, and home-based intervention models, therapies like ENBUMYST may play an important role in enabling earlier clinical response. For patients, this approach may translate to fewer unplanned healthcare encounters, greater treatment continuity, and the potential for improved quality of life when medication can be administered during the early window of symptom change.
For the broader healthcare system, the trend toward outpatient intervention aligns with value-based care objectives, including improved care consistency, reduction in avoidable high-cost encounters, and greater alignment between treatment delivery and patient-preferred care settings.
Corstasis and CVL expect the implementation phase of the collaboration to roll out in stages across select Corstasis cardiovascular practices, with planned expansion as operational processes, feedback loops, and educational frameworks mature. Both organizations reaffirm that patient safety, physician autonomy, and regulatory compliance remain foundational to the initiative.
Source Link: https://www.businesswire.com/
